Sirnaomics, Inc.

42 articles about Sirnaomics, Inc.

• Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

  12/1/2023

  Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

• Sirnaomics Announces 2023 Interim Results

  8/31/2023

  Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has announced its interim results for the six months ended 30 June 2023.

• Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

  8/31/2023

  Sirnaomics Ltd. announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments.

• Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

  7/28/2023

  Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

• Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences

  7/12/2023

  Sirnaomics Ltd. hereby announces that Sirnaomics' Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July.

• Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company

  7/5/2023

  Sirnaomics Ltd. announced that the Company has established a strategic partnership with EDIRNA Inc., an early-stage biotech company focused on RNA-Editing therapeutic company, for advancing its proprietary "Edit-to-Cure Therapeutics™" platform, targeting diseases with high unmet clinical need.

• Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

  6/19/2023

  Sirnaomics Ltd. today announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results were shared with the U.S. Food and Drug Administration (FDA) in an End of Phase-2 meeting.

• Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

  6/5/2023

  Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the interim results of an ongoing Phase I clinical trial of STP705, an siRNA drug candidate, for fat reduction in adults undergoing abdominoplasty.

• Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

  6/1/2023

  Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced it has dosed the first participant in a Phase I clinical trial of STP122G for anticoagulation treatment.

• Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

  5/17/2023

  Sirnaomics Ltd. has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation, which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.

• Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

  4/12/2023

  Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the launch of a Phase I clinical trial of STP122G based on the Group's GalNAc Factor XI Program.

• Sirnaomics Announces 2022 Annual Results

  3/28/2023

  Sirnaomics Ltd. has announced its audited annual results for the year ended 31 December 2022 (the "Year").

• Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

  3/20/2023

  Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics") announced today that Dr. Patrick Lu, Chairman of the Board, Executive Director, President and Chief Executive Officer and Dr. Richard W. Welch, Vice President of  Chemistry, Manufacturing, and Controls processes (CMC), will deliver keynote speeches during the 4th Annual RNAi-Based Therapeutic Summit.

• Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

  2/1/2023

  Sirnaomics Ltd. announced that it is advancing the clinical development of STP705 for the treatment of two non-melanoma skin cancers: Squamous Cell Carcinoma in situ and Basal Cell Carcinoma.

• Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

  12/20/2022

  Sirnaomics Ltd. announced today the interim results from a Phase I clinical trial evaluating the safety, tolerability and anti-tumor activity of the Company's siRNA (small interfering RNA) drug candidate, STP707 with intravenous (IV) administration in the United States.

• Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland

  12/19/2022

  Sirnaomics Ltd. and its affiliates and subsidiaries, a leading biopharmaceutical company in discovery and development of RNAi therapeutics, celebrated Sirnaomics' 15th anniversary of RNAi therapeutic innovation globally, along with the grand opening of the new headquarters and laboratories for its US subsidiary in Germantown, Maryland, on Dec. 15, 2022.

• Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ

  12/14/2022

  Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results of part-one of an ongoing Phase IIb clinical trial of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC).

• Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

  12/13/2022

  Sirnaomics Ltd. announced that its Executive Director Dr. Xiaochang Dai will deliver a keynote speech at BIOHK2022, the first major biotech conference to be held in Hong Kong since the outbreak of the COVID-19 pandemic.

• Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

  10/19/2022

  Sirnaomics Ltd. announced that it will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme.

• Sirnaomics to Present at 3rd Annual Jefferies Asia Forum

  9/7/2022

  Sirnaomics Ltd. announced that Dr. Patrick Lu, PhD, founder, Chairman of the Board, Executive Director, President, and CEO of Sirnaomics, will present at the 3rd Annual Jefferies Asia Forum that will be held on September 8, 2022.